Zacks Research Upgrades Phibro Animal Health (NASDAQ:PAHC) to Strong-Buy

Phibro Animal Health (NASDAQ:PAHC) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Wednesday,Zacks.com reports. Zacks Research also issued estimates for Phibro Animal Health’s Q3 2026 earnings at $0.72 EPS, Q4 2026 earnings at $0.66 EPS, FY2026 earnings at $2.98 EPS, Q1 2027 earnings at $0.77 EPS, Q2 2027 earnings at $0.78 EPS, FY2027 earnings at $3.05 EPS, Q1 2028 earnings at $0.79 EPS and FY2028 earnings at $3.17 EPS.

A number of other research firms also recently commented on PAHC. Morgan Stanley set a $49.00 price target on Phibro Animal Health in a research note on Friday, February 6th. Weiss Ratings reissued a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Phibro Animal Health has an average rating of “Moderate Buy” and an average price target of $37.50.

Phibro Animal Health Price Performance

Phibro Animal Health stock opened at $49.00 on Wednesday. The firm has a market cap of $1.99 billion, a PE ratio of 21.78, a price-to-earnings-growth ratio of 0.77 and a beta of 0.74. The company has a debt-to-equity ratio of 2.14, a current ratio of 3.05 and a quick ratio of 1.22. The stock’s fifty day moving average price is $46.07 and its two-hundred day moving average price is $42.06. Phibro Animal Health has a one year low of $16.16 and a one year high of $56.30.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.18. The firm had revenue of $373.91 million during the quarter, compared to the consensus estimate of $355.64 million. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. As a group, research analysts expect that Phibro Animal Health will post 1.95 EPS for the current fiscal year.

Insider Buying and Selling at Phibro Animal Health

In related news, CEO Jack Bendheim sold 7,040 shares of the company’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $53.73, for a total transaction of $378,259.20. Following the completion of the sale, the chief executive officer directly owned 1,480 shares in the company, valued at $79,520.40. This represents a 82.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders sold 288,640 shares of company stock worth $13,821,518. 50.13% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Phibro Animal Health by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock worth $260,000 after acquiring an additional 546 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Phibro Animal Health by 74.3% during the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock valued at $7,733,000 after purchasing an additional 154,281 shares during the last quarter. Jane Street Group LLC grew its holdings in shares of Phibro Animal Health by 65.3% during the 1st quarter. Jane Street Group LLC now owns 33,917 shares of the company’s stock valued at $724,000 after purchasing an additional 13,404 shares during the last quarter. Envestnet Asset Management Inc. increased its position in Phibro Animal Health by 97.3% during the 2nd quarter. Envestnet Asset Management Inc. now owns 24,334 shares of the company’s stock worth $621,000 after purchasing an additional 11,999 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Phibro Animal Health by 0.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 268,877 shares of the company’s stock valued at $6,867,000 after purchasing an additional 906 shares during the last quarter. Institutional investors and hedge funds own 99.34% of the company’s stock.

Trending Headlines about Phibro Animal Health

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Zacks Research raised several near‑term and multi‑year EPS estimates for PAHC: small bumps to Q3/Q4 FY2026 and Q1–Q2 FY2027 quarterly estimates (e.g., Q3 2026 to $0.72, Q4 2026 to $0.66, Q1 2027 to $0.77, Q2 2027 to $0.78) and modest increases to FY2026–FY2028 targets (FY2026 to $2.98, FY2027 to $3.05, FY2028 to $3.17). Zacks still lists a “Hold” rating, but the revisions signal slightly improved analyst expectations for earnings power.
• Positive Sentiment: Zacks included PAHC on its March 12 “Best Value Stocks to Buy” list (Zacks Rank #1 value), which can attract value‑focused buying and short‑term attention from investors. Best Value Stocks to Buy for March 12th

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.